Dr. Jack Regan, CEO LexaGene and BioPub Investment Interview – January 26, 2022

by LexaGene | Feb 1, 2022 | Veterinary Diagnostics

Home » Veterinary Diagnostics » Dr. Jack Regan, CEO LexaGene and BioPub Investment Interview – January 26, 2022

Watch the video below for Dr. Jack Regan’s recent interview with BioPub.

LexaGene

LexaGene develops fully automated, rapid molecular testing at the point-of-need for accurate pathogen detection in human clinical diagnostics, veterinary diagnostics, food safety, and other markets.

Survey Says Veterinarians Have an Appetite for In-Clinic Diagnostic Technology

This spring LexaGene conducted a market research survey in conjunction with AAHA to assess the opinions of practicing veterinarians on AMR stewardship and the use of antibiotics in the treatment of companion animals.

The Dawn of the Superbugs

The most menacing of all resistant bacteria are the so called “super bugs”- strains of bacteria that are resistant to several different classes of antibiotics or multidrug resistant.

LexaGene offers North Shore Technology Council (NSTC) and Leadership Team at MassBio a tour of our Beverly Facility

Recently, we welcomed members of North Shore Technology Council and MassBio Leadership Teams into our facility at 500 Cummings Center for a full tour of our office space and laboratory spaces.

Subscribe for Updates